Arcus Biosciences (NYSE: RCUS) reported Q1 EPS of ($0.96), $0.65 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $18 million versus the consensus estimate of $79.42 million.

Cash, cash equivalents and investments were $1,342.4 million as of March 31, 2022, compared to $681.3 million as of December 31, 2021. The increase was primarily due to the receipt of $725 million from Gilead in January 2022. Arcus expects cash, cash equivalents and marketable securities on-hand to be sufficient to fund operations into 2026.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.